I. P. Romanova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
I. P. Romanova has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- O. O. Buriakovska
ДУ «Національний інститут терапії імені Л. Т. Малої НАМН України», Харків
3 shared publications - Nonna Kravchun
Kharkiv National Medical University, Kharkiv, Ukraine; SI «V. Danilevsky Institute for Endocrine Pathology Problems of the NAMS of Ukraine»
2 shared publications - O. A. Goncharova
ДУ «Інститут проблем ендокринної патології імені В. Я. Данилевського НАМН України», Харків; Харківський національний медичний університет
2 shared publications - I. P. Dunaieva
Kharkiv National Medical University
1 shared publication I.I. Kniazkova
Kharkiv National Medical University Ministry of Health of Ukraine, Department of Clinical Pharmacology and Internal Medicine, L. Maloi ave., 2a, Kharkiv, 61039, Ukraine
1 shared publication- O.D. Kurilo
SI «V. Danilevsky Institute for Endocrine Pathology Problems of the National Academy of Medical Sciences of Ukraine», Department of Clinical Endocrinology, Alchevskykh str., 10, Kharkiv, 61002, Ukraine
1 shared publication
Latest Publications
- Open Access
- 31 March 2026
- Published by Publishing Company VIT-A-POL in Ukrainian Therapeutical Journal
- No. 1,p. 16-20
Deintensification of insulin therapy in type 2 diabetes mellitus. Clinical case
Using a clinical example of insulindependent type 2 diabetes mellitus in a young woman, the features of clinical symptoms, the course of the disease, and the difficulties of achieving glycemic targets and weight control in a fairly large cohort of patients are examined. Diabetes mellitus is a very common disease that leads to both serious complications and worsens the course of concomitant diseases. According to the World Health Organization, the rate of development and spread of diabetes mellitus is rapidly increasing every year and is gaining momentum as a pandemic. The most common and most disabling type of diabetes mellitus is type 2. Despite a fairly wide range of oral hypoglycemic drugs, a large number of patients are prescribed insulin therapy due to the progressive nature of diabetes and the inability to achieve glycemic targets. This article emphasizes the importance of a personalized and patientcentered approach to patients with type 2 diabetes mellitus. It details the priorities, risks, and potential adverse effects of adding basalbolus insulin therapy to oral agents in patients with type 2 diabetes mellitus. The complaints, medical history, objective status, laboratory and instrumental data of the patient, who had been obese since childhood, had type 2 diabetes mellitus from the age of 31, and was transferred to insulin therapy from the age of 36, are presented in detail. Possible treatment methods are discussed, combinations of various oral hypoglycemic drugs with insulin therapy in different regimens. A scheme for deintensification of insulin therapy and the dynamics of glycemia indicators according to laboratory data, as well as continuous glycemia monitoring, are presented. The analysis of the literature data on the disease was conducted. It is emphasized that it is necessary to regularly observe such patients for timely correction and selection of therapy and reduce the risk of developing both early and delayed complications.
- 31 March 2026
- Published by Publishing Company VIT-A-POL in Ukrainian Therapeutical Journal
- No. 1,p. 16-20
Open AccessDeintensification of insulin therapy in type 2 diabetes mellitus. Clinical case
Using a clinical example of insulindependent type 2 diabetes mellitus in a young woman, the features of clinical symptoms, the course of the disease, and the difficulties of achieving glycemic targets and weight control in a fairly large cohort of patients are examined. Diabetes mellitus is a very common disease that leads to both serious complications and worsens the course of concomitant diseases. According to the World Health Organization, the rate of development and spread of diabetes mellitus is rapidly increasing every year and is gaining momentum as a pandemic. The most common and most disabling type of diabetes mellitus is type 2. Despite a fairly wide range of oral hypoglycemic drugs, a large number of patients are prescribed insulin therapy due to the progressive nature of diabetes and the inability to achieve glycemic targets. This article emphasizes the importance of a personalized and patientcentered approach to patients with type 2 diabetes mellitus. It details the priorities, risks, and potential adverse effects of adding basalbolus insulin therapy to oral agents in patients with type 2 diabetes mellitus. The complaints, medical history, objective status, laboratory and instrumental data of the patient, who had been obese since childhood, had type 2 diabetes mellitus from the age of 31, and was transferred to insulin therapy from the age of 36, are presented in detail. Possible treatment methods are discussed, combinations of various oral hypoglycemic drugs with insulin therapy in different regimens. A scheme for deintensification of insulin therapy and the dynamics of glycemia indicators according to laboratory data, as well as continuous glycemia monitoring, are presented. The analysis of the literature data on the disease was conducted. It is emphasized that it is necessary to regularly observe such patients for timely correction and selection of therapy and reduce the risk of developing both early and delayed complications.
- Open Access
- 30 December 2025
- Published by Publishing Company VIT-A-POL in Ukrainian Therapeutical Journal
- No. 4,p. 33-37
A rare form of type 3c diabetes mellitus. Clinical case
On a clinical example of type 3c diabetes mellitus in a young man of 40 years, the peculiarities of clinical symptoms and the difficulties of diagnosing this disease are considered. Diabetes mellitus is a fairly common disease that leads to severe disabling complications and worsens the course of concomitant diseases. According to the World Health Organization, the rate of development and spread of diabetes is rapidly increasing every year and is gaining momentum as a pandemic. The most common type of diabetes mellitus is type 2. Type 3c diabetes mellitus is a rare form that was first announced in 2011 by the American Diabetes Association together with the World Health Organization. This type of diabetes is secondary diabetes that develops due to the destruction or loss of pancreatic tissue and accounts for up to 8% of all diabetes mellitus cases. In this article, special attention is paid to the importance of thorough examination and follow-up of patients who have undergone acute or chronic inflammatory processes of the pancreas or surgical interventions on the pancreas. The data of a patient who suffered acute pancreatitis in 2014, had regular exacerbations of chronic pancreatitis for 10 years, and had a diabetes mellitus manifest in 2023 are presented in detail. Diagnostic criteria of diabetes mellitus type 3c according to modern recommendations are described. Criteria for differential diagnosis of types of diabetes mellitus are provided. Possible methods of treatment of this disease are discussed. The features of the course of diabetes mellitus type 3c, the risk of developing hypoglycemic states in such patients, and the target glycemic goals, as well as the possibilities of their achievement, are discussed. An analysis of data from the literature of the disease was carried out. It is emphasized that it is necessary to regularly observe such patients for timely diagnosis, selection of correct therapy and reduction of the risk of developing both early and delayed complications.
- 30 December 2025
- Published by Publishing Company VIT-A-POL in Ukrainian Therapeutical Journal
- No. 4,p. 33-37
Open AccessA rare form of type 3c diabetes mellitus. Clinical case
On a clinical example of type 3c diabetes mellitus in a young man of 40 years, the peculiarities of clinical symptoms and the difficulties of diagnosing this disease are considered. Diabetes mellitus is a fairly common disease that leads to severe disabling complications and worsens the course of concomitant diseases. According to the World Health Organization, the rate of development and spread of diabetes is rapidly increasing every year and is gaining momentum as a pandemic. The most common type of diabetes mellitus is type 2. Type 3c diabetes mellitus is a rare form that was first announced in 2011 by the American Diabetes Association together with the World Health Organization. This type of diabetes is secondary diabetes that develops due to the destruction or loss of pancreatic tissue and accounts for up to 8% of all diabetes mellitus cases. In this article, special attention is paid to the importance of thorough examination and follow-up of patients who have undergone acute or chronic inflammatory processes of the pancreas or surgical interventions on the pancreas. The data of a patient who suffered acute pancreatitis in 2014, had regular exacerbations of chronic pancreatitis for 10 years, and had a diabetes mellitus manifest in 2023 are presented in detail. Diagnostic criteria of diabetes mellitus type 3c according to modern recommendations are described. Criteria for differential diagnosis of types of diabetes mellitus are provided. Possible methods of treatment of this disease are discussed. The features of the course of diabetes mellitus type 3c, the risk of developing hypoglycemic states in such patients, and the target glycemic goals, as well as the possibilities of their achievement, are discussed. An analysis of data from the literature of the disease was carried out. It is emphasized that it is necessary to regularly observe such patients for timely diagnosis, selection of correct therapy and reduction of the risk of developing both early and delayed complications.
- Open Access
- 31 March 2024
- Published by Publishing Company VIT-A-POL in Ukrainian Therapeutical Journal
- No. 1,p. 49-52
Clinical case of autoimmune polyglandular syndrome type II
The peculiarities of clinical symptoms and the difficulties of diagnosing have been considered on the clinical example of manifestations of autoimmune polyglandular syndrome type II in a young woman. Autoimmune polyglandular syndrome type II is a rather rare pathology, its prevalence is 1 : 20.000 cases of the population. The diagnosis of this disease is determined by the presence of insufficiency of at least two endocrine glands with mandatory adrenal insufficiency. The second component of the disease can be any autoimmune thyroid disease or type 1 diabetes mellitus, which is also autoimmune in nature, or both conditions. Adrenal insufficiency is the initial manifestation of this syndrome in approximately 50% of patients, occurs simultaneously with autoimmune thyroiditis or type 1 diabetes in 20% of patients, the remaining 30% of patients may have a different sequence of manifest components of autoimmune polyglandular syndrome type II. In this article, special attention is paid to the importance of careful monitoring of patients with at least one autoimmune disorder of endocrine organ. The data presents in detail a history of patient who had only type 1 diabetes and autoimmune thyroiditis for 7 years, and the manifestation of adrenal insufficiency was registered 7 years after the manifestation of the primary components of autoimmune polyglandular syndrome type II. The authors highlighted diagnostically significant changes in laboratory methods. The analysis has been performed for the literature data, related to the disease. The necessary to observe patients regularly for quick diagnosis and to reduce the risk of developing both immediate and delayed complications has been emphasized. Special attention should be paid to the examination of relatives of the first line of kinship among patients with the established diagnosis of autoimmune polyglandular syndrome type II for the presence of possible heredity.
- 31 March 2024
- Published by Publishing Company VIT-A-POL in Ukrainian Therapeutical Journal
- No. 1,p. 49-52
Open AccessClinical case of autoimmune polyglandular syndrome type II
The peculiarities of clinical symptoms and the difficulties of diagnosing have been considered on the clinical example of manifestations of autoimmune polyglandular syndrome type II in a young woman. Autoimmune polyglandular syndrome type II is a rather rare pathology, its prevalence is 1 : 20.000 cases of the population. The diagnosis of this disease is determined by the presence of insufficiency of at least two endocrine glands with mandatory adrenal insufficiency. The second component of the disease can be any autoimmune thyroid disease or type 1 diabetes mellitus, which is also autoimmune in nature, or both conditions. Adrenal insufficiency is the initial manifestation of this syndrome in approximately 50% of patients, occurs simultaneously with autoimmune thyroiditis or type 1 diabetes in 20% of patients, the remaining 30% of patients may have a different sequence of manifest components of autoimmune polyglandular syndrome type II. In this article, special attention is paid to the importance of careful monitoring of patients with at least one autoimmune disorder of endocrine organ. The data presents in detail a history of patient who had only type 1 diabetes and autoimmune thyroiditis for 7 years, and the manifestation of adrenal insufficiency was registered 7 years after the manifestation of the primary components of autoimmune polyglandular syndrome type II. The authors highlighted diagnostically significant changes in laboratory methods. The analysis has been performed for the literature data, related to the disease. The necessary to observe patients regularly for quick diagnosis and to reduce the risk of developing both immediate and delayed complications has been emphasized. Special attention should be paid to the examination of relatives of the first line of kinship among patients with the established diagnosis of autoimmune polyglandular syndrome type II for the presence of possible heredity.
- Open Access
- 18 June 2021
- Published by Dnipro State Medical University in Medicni perspektivi
- Vol. 26 (2) , 126-134
Hepatic fibrosis as an additional risk factor for the development of cardiovascular disorders in patients with type 2 diabetes mellitus with non-alcoholic fatty liver disease
The aim of the study was to determine the relationship between the degree of progression of liver fibrosis and the risk of cardiovascular complications in patients with Type 2 diabetes mellitus (DM) with non-alcoholic fatty liver disease (NAFLD). The study included 110 patients with Type 2 diabetes (62 men and 48 women), the average age of the subjects was 52.07±1.11 years. All patients were divided into 2 groups: the main group included 72 patients with Type 2 diabetes with concomitant NAFLD (38 men and 34 women); the control group included 38 patients with Type 2 diabetes without clinical manifestations of NAFLD (24 men and 14 women). Patients of the main group were divided into 3 subgroups, taking into account the predominant pathological processes in the clinical picture. The division into subgroups was carried out in 2 stages: at the first stage, those with predominant manifestations of liver fibrosis (F2 or more) were selected from the general population of patients with Type 2 diabetes with NAFLD according to the results of liver elastography and the use of Bonacini and Metavir scales. The number of such patients was 29, which accounted for 40.3% of the total number of patients in the main group. The remaining patients were divided into 2 subgroups: 11 patients (15.3%) had non-alcoholic liver steatosis, and 32 patients (44.4%) had signs of non-alcoholic steatohepatitis (NASH). As a result of the study, it was found that the presence of liver fibrosis in patients with Type 2 diabetes with NAFLD is significantly more often associated with cardiovascular complications, such as arterial hypertension, coronary heart disease, myocardial infarction, stroke, diabetic retinopathy and nephropathy. A significant decrease in the ejection fraction (EF) was found in patients with Type 2 diabetes with concomitant NAFLD. At the same time, the number of patients with EF disorders of varying degrees in the main group significantly exceeded that in the comparison group (33.3% and 6.7%, respectively, p<0.001). The average values of left ventricular myocardial mass are significantly lower in patients with NASH and fibrosis formation compared to patients with NAFLD at the stage of fatty hepatosis. There was also a significant decrease in the size of the left and right atria in patients with NASH compared to both patients with steatosis and patients with fibrotic liver changes. Patients with predominant fibrotic changes in the liver are characterized by a relative decrease in myocardial mass, a decrease in final diastolic and systolic volumes and EF, which may indicate the development of diastolic dysfunction in them. It is shown that it is necessary to take into account in clinical practice not only the generally accepted stages of NAFLD, but also the predominant pathological process in the liver in patients with Type 2 diabetes, namely steatosis, manifestations of inflammation and fibrotic disorders. It is proved that fibrotic changes in the liver can develop at all stages of liver tissue damage.
- 18 June 2021
- Published by Dnipro State Medical University in Medicni perspektivi
- Vol. 26 (2) , 126-134
Open AccessHepatic fibrosis as an additional risk factor for the development of cardiovascular disorders in patients with type 2 diabetes mellitus with non-alcoholic fatty liver disease
The aim of the study was to determine the relationship between the degree of progression of liver fibrosis and the risk of cardiovascular complications in patients with Type 2 diabetes mellitus (DM) with non-alcoholic fatty liver disease (NAFLD). The study included 110 patients with Type 2 diabetes (62 men and 48 women), the average age of the subjects was 52.07±1.11 years. All patients were divided into 2 groups: the main group included 72 patients with Type 2 diabetes with concomitant NAFLD (38 men and 34 women); the control group included 38 patients with Type 2 diabetes without clinical manifestations of NAFLD (24 men and 14 women). Patients of the main group were divided into 3 subgroups, taking into account the predominant pathological processes in the clinical picture. The division into subgroups was carried out in 2 stages: at the first stage, those with predominant manifestations of liver fibrosis (F2 or more) were selected from the general population of patients with Type 2 diabetes with NAFLD according to the results of liver elastography and the use of Bonacini and Metavir scales. The number of such patients was 29, which accounted for 40.3% of the total number of patients in the main group. The remaining patients were divided into 2 subgroups: 11 patients (15.3%) had non-alcoholic liver steatosis, and 32 patients (44.4%) had signs of non-alcoholic steatohepatitis (NASH). As a result of the study, it was found that the presence of liver fibrosis in patients with Type 2 diabetes with NAFLD is significantly more often associated with cardiovascular complications, such as arterial hypertension, coronary heart disease, myocardial infarction, stroke, diabetic retinopathy and nephropathy. A significant decrease in the ejection fraction (EF) was found in patients with Type 2 diabetes with concomitant NAFLD. At the same time, the number of patients with EF disorders of varying degrees in the main group significantly exceeded that in the comparison group (33.3% and 6.7%, respectively, p<0.001). The average values of left ventricular myocardial mass are significantly lower in patients with NASH and fibrosis formation compared to patients with NAFLD at the stage of fatty hepatosis. There was also a significant decrease in the size of the left and right atria in patients with NASH compared to both patients with steatosis and patients with fibrotic liver changes. Patients with predominant fibrotic changes in the liver are characterized by a relative decrease in myocardial mass, a decrease in final diastolic and systolic volumes and EF, which may indicate the development of diastolic dysfunction in them. It is shown that it is necessary to take into account in clinical practice not only the generally accepted stages of NAFLD, but also the predominant pathological process in the liver in patients with Type 2 diabetes, namely steatosis, manifestations of inflammation and fibrotic disorders. It is proved that fibrotic changes in the liver can develop at all stages of liver tissue damage.